Drug Effects on Physiology, Drug Kinetics
Conditions
Brief summary
This single center, single ascending dose (SAD) and repeat dose study in healthy adults comprises 2 parts. Part 1 will consist of 6 SAD cohorts, in which different dose levels of sargramostim will be given by intravenous (IV) infusion, subcutaneous (SC) injection, or inhalation (IH) administration. Part 2 will consist of 1 repeat dose cohort in which sargramostim will begiven by SC administration. Blood samples for PK assessment will be collected before and over 24 hours after each study drug administration. Blood samples for PD assessment will be collected before and up to 14 days after drug administration in Part 1, as well as before the first and up to 14 days after the second drug administration in Part 2. Safety and tolerability will be assessed throughout the study. For Cohort 5 of Part 1 only, 3 subjects will provide a CSF sample for PK assessmen tonce after SC drug administration.
Interventions
BIOLOGICALsargramostim
Sargramostim is a glycosylated, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.
Sponsors
Partner Therapeutics, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adult male and female participants * Nonsmoker or ex-smoker * Able to provide informed consent and comply with all study procedures * Body Mass Index within 18.5-30.0 kilograms/meter squared, inclusive * Females of childbearing potential willing to use highly-effective method of birth control.
Exclusion criteria
* Females who are pregnant or breastfeeding * History of allergic to sargramostim or its excipients, other human GM-CSFs, or other yeast-derived products. * History of severe allergic reactions to other drugs. * History of or any current medical condition or laboratory finding that may jeopardize completion of the study, present an increased risk to the subject, or compromise interpretation of the study. . * Immunization with COVID-19 vaccine within 14 days of the study. * Scheduled immunization with COVID-19 vaccine during the study * Use of prescription drugs within 28 days of the study or requirement for maintenance drugs during the study. * Participation in another investigational drug study within 28 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Steady state volume of distribution (IV administration only) | Blood samples collected up to 24 hours post dose |
| AUC from time 0 to infinity | Blood samples collected up to 24 hours post dose |
| AUC from time 0 to 24 hours/infinity | Blood samples collected up to 24 hours post dose |
| Elimination half-life | Blood samples collected up to 24 hours post dose |
| Clearance | Blood samples collected up to 24 hours post dose |
| maximum concentration | Blood samples collected up to 24 hours post dose |
| time to maximum | Blood samples collected up to 24 hours post dose |
| Area under the concentration-time curve (AUC) from time 0 to 24 hours | Blood samples collected up to 24 hours post dose |
Secondary
| Measure | Time frame |
|---|---|
| Number of subjects with adverse events in Part 2 | Up to Day 22 in Part 2 |
| Ratio of T-regulatory cells to T-effector cells in the blood. | Up to Day 15 in Part 1, up to Day 22 in Part 2 |
| CD14/CD16/human leukocyte antigen-DR isotype (HLA-DR) absolute cell count | Up to Day 15 in Part 1, up to Day 22 in Part 2 |
| Number of subjects with adverse events in Part 1 | Up to Day 15 in Part 1 |
Countries
Canada
Outcome results
None listed